Market Chatter: Chabiotech Subsidiary Matica Biotechnology Signs Viral Vector CDMO Deals with US Biotech Firms

MT Newswires Live10-16

Chabiotech (KOSDAQ:A085660) subsidiary Matica Biotechnology secured contract development and manufacturing organization (CDMO) contracts with Puerto Rico-based biotechnology company CytoImmune Therapeutics and Mongoose Bio for cell and gene therapies, Pulse News reported Wednesday.

Under the collaboration, Matica Bio will produce viral vectors at its dedicated good manufacturing practice (GMP) facility, while CytoImmune will handle cell therapy production at its Puerto Rico site for IND submission, Matica said last week.

Mongoose Bio will develop T-cell therapies for solid tumors with Matica's lentiviral vectors, the news report said.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: $17750.00, Change: $-80, Percent Change: -0.45%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2475965261?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-16 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475965261","market":"fut","top_or_hot":-1,"title":"Market Chatter: Chabiotech Subsidiary Matica Biotechnology Signs Viral Vector CDMO Deals with US Biotech Firms","media":"MT Newswires Live","content":"<html><body><p> Chabiotech (KOSDAQ:A085660) subsidiary Matica Biotechnology secured contract development and manufacturing organization (CDMO) contracts with Puerto Rico-based biotechnology company CytoImmune <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and Mongoose Bio for cell and gene therapies, Pulse News reported Wednesday.</p><p>Under the collaboration, Matica Bio will produce viral vectors at its dedicated good manufacturing practice (GMP) facility, while CytoImmune will handle cell therapy production at its Puerto Rico site for IND submission, Matica said last week.</p><p>Mongoose Bio will develop T-cell therapies for solid tumors with Matica's lentiviral vectors, the news report said.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p><p>Price: $17750.00, Change: $-80, Percent Change: -0.45%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: Chabiotech Subsidiary Matica Biotechnology Signs Viral Vector CDMO Deals with US Biotech Firms</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: Chabiotech Subsidiary Matica Biotechnology Signs Viral Vector CDMO Deals with US Biotech Firms\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-16 19:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chabiotech (KOSDAQ:A085660) subsidiary Matica Biotechnology secured contract development and manufacturing organization (CDMO) contracts with Puerto Rico-based biotechnology company CytoImmune ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VGR","symbol_name":"Vector Group Ltd.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2475965261","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475965261","pubTimestamp":1729076699,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Chabiotech  subsidiary Matica Biotechnology secured contract development and manufacturing organization  contracts with Puerto Rico-based biotechnology company CytoImmune Therapeutics and Mongoose Bio for cell and gene therapies, Pulse News reported Wednesday.Under the collaboration, Matica Bio will produce viral vectors at its dedicated good manufacturing practice  facility, while CytoImmune will handle cell therapy production at its Puerto Rico site for IND submission, Matica said last week.Mongoose Bio will develop T-cell therapies for solid tumors with Matica's lentiviral vectors, the news report said.Price: $17750.00, Change: $-80, Percent Change: -0.45%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VGR":"Vector Group Ltd.","BK4561":"索罗斯持仓","VAQC":"Vector Acquisition Corporation II","BK4139":"生物科技","CDMO":"Avid Bioservices, Inc.","BK4075":"烟草"},"translate_title":"市场热议：Chabiotech子公司Matica Biotechnology与美国生物技术公司签署病毒载体CDMO协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDMO":1,"VAQC":1,"VGR":1},"content_text":"Chabiotech (KOSDAQ:A085660) subsidiary Matica Biotechnology secured contract development and manufacturing organization (CDMO) contracts with Puerto Rico-based biotechnology company CytoImmune Therapeutics and Mongoose Bio for cell and gene therapies, Pulse News reported Wednesday.Under the collaboration, Matica Bio will produce viral vectors at its dedicated good manufacturing practice (GMP) facility, while CytoImmune will handle cell therapy production at its Puerto Rico site for IND submission, Matica said last week.Mongoose Bio will develop T-cell therapies for solid tumors with Matica's lentiviral vectors, the news report said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $17750.00, Change: $-80, Percent Change: -0.45%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2475965261"}